Dermira, Inc. (NASDAQ:DERM) CEO Thomas G. Wiggans sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $27.52, for a total transaction of $137,600.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Thomas G. Wiggans also recently made the following trade(s):

  • On Monday, September 18th, Thomas G. Wiggans sold 9,500 shares of Dermira stock. The stock was sold at an average price of $27.51, for a total transaction of $261,345.00.
  • On Tuesday, August 1st, Thomas G. Wiggans sold 500 shares of Dermira stock. The stock was sold at an average price of $27.58, for a total transaction of $13,790.00.

Shares of Dermira, Inc. (DERM) traded down 0.10% during mid-day trading on Wednesday, hitting $28.64. 1,243,357 shares of the stock traded hands. Dermira, Inc. has a 1-year low of $21.35 and a 1-year high of $38.75. The company’s 50-day moving average price is $25.80 and its 200 day moving average price is $28.48. The company’s market capitalization is $1.19 billion.

Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.04). The firm had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.00 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. Equities research analysts forecast that Dermira, Inc. will post ($4.20) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/11/insider-selling-dermira-inc-derm-ceo-sells-5000-shares-of-stock.html.

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA boosted its stake in Dermira by 2,220.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 3,975 shares in the last quarter. SG Americas Securities LLC raised its position in Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 2,203 shares during the last quarter. KCG Holdings Inc. purchased a new position in Dermira in the 1st quarter worth about $215,000. Legal & General Group Plc raised its position in Dermira by 16.3% in the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 963 shares during the last quarter. Finally, Ardsley Advisory Partners purchased a new position in Dermira in the 2nd quarter worth about $291,000. Institutional investors own 97.56% of the company’s stock.

Several research firms have weighed in on DERM. BidaskClub downgraded shares of Dermira from a “sell” rating to a “strong sell” rating in a report on Thursday, August 10th. Cantor Fitzgerald restated a “buy” rating and set a $45.00 price objective on shares of Dermira in a report on Tuesday, September 26th. Needham & Company LLC restated a “buy” rating and set a $46.00 price objective on shares of Dermira in a report on Sunday, September 17th. Evercore ISI initiated coverage on shares of Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 target price for the company. Finally, Mizuho reiterated a “buy” rating and issued a $43.00 target price (up previously from $40.00) on shares of Dermira in a report on Thursday, September 7th. Four analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $44.40.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.